This narrative review maps next-generation anti-obesity agents, ultralong-acting incretins, oral formulations, multi-receptor agonists, and lean-mass-sparing pathways, giving endocrinology and obesity pharmacists a forward view of the pipeline.
📅 Journal publication: Jul 7, 2026·Last updated: Aug 5, 2026
Innovative anti-obesity drugs offer hope beyond current treatments.
Obesity is a growing global issue with current treatments presenting challenges like adverse effects and rebound weight gain, highlighting the need for new therapies. The review identifies potential non-incretin pharmacological targets and novel anti-obesity drug candidates for further clinical validation. While promising, these emerging therapies require more clinical trials to assess their safety and efficacy compared to current options before influencing practice. New non-incretin anti-obesity drugs are on the horizon, offering hope for safer, more effective treatments.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Lee S, Song H, Kwon Y
Citation:Lee S, Song H, Kwon Y A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. Pharmaceuticals (Basel, Switzerland). 2026;19(7). doi:10.3390/ph19071047